The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

COPENHAGEN, Feb 3 () - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% this year ...

Governor Maura Healey and Denmark’s Ambassador to the U.S., Jesper Møller Sørensen, signed an economic partnership agreement ...

COPENHAGEN, Feb 3 () - ​Wegovy ‌maker Novo ‌Nordisk expects a decline ⁠in ‌sales this year, ‍it said on ​Tuesday ‌as it reported fourth-quarter operating profit ⁠slightly above ​forecasts. (Reporting ...

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates ...

Bagsværd, Denmark, 3 February 2026 - Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and ...

Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 billion. Had Novo Nordisk not incurred costs related to the company-wide ...

Effective prevention and management of type 2 diabetes can improve patient outcomes and reduce health care-related environmental impact.

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...